MetaCap

Werewolf Therapeutics (HOWL) vs Milestone Pharmaceuticals (MIST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Werewolf Therapeutics (HOWL) has outperformed Milestone Pharmaceuticals (MIST) over the past year, gaining 8.4% versus a loss of 84.5%. Over five years, HOWL leads with a -93.7% price change compared with -93.8% for MIST. Milestone Pharmaceuticals is the larger company by market cap ($46.2 million vs $46.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HOWL+8.43%MIST-84.54%
+32%-29%-90%
Nov 21, 20251 yearNov 20, 2026
HOWL-94.08%MIST-93.88%
+65%-21%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HOWL versus MIST key metrics
MetricHOWLMIST
Share price$0.9466$0.3711
Market cap$46.00M$46.20M
1-day change-3.97%-7.06%
YTD return+49.31%-81.63%
1-year return+8.43%-84.54%
5-year return-93.68%-93.85%
EPS (TTM)$-0.58$-0.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-60.82M$-63.06M
52-week high$1.20$3.06
52-week low$0.27$0.362
Distance from 52-week high-21.12%-87.87%
Analyst consensusnonenone
Avg. price target upside+639.49%+1479.09%
Average volume1.08M1.53M
Shares outstanding48.60M124.50M
Employees3938
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HOWL has outperformed MIST by 93.0 percentage points over the past year.

About Werewolf Therapeutics

HOWL stock →

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees

About Milestone Pharmaceuticals

MIST stock →

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

HOWL vs MIST FAQ

Which is bigger, Werewolf Therapeutics or Milestone Pharmaceuticals?

Milestone Pharmaceuticals (MIST) is larger, with a market capitalization of $46.20M compared with $46.00M for Werewolf Therapeutics (HOWL).

Which stock has performed better over the past year, HOWL or MIST?

HOWL returned +8.43% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.

Are Werewolf Therapeutics and Milestone Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons